NO151288B - ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS - Google Patents

ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS Download PDF

Info

Publication number
NO151288B
NO151288B NO783958A NO783958A NO151288B NO 151288 B NO151288 B NO 151288B NO 783958 A NO783958 A NO 783958A NO 783958 A NO783958 A NO 783958A NO 151288 B NO151288 B NO 151288B
Authority
NO
Norway
Prior art keywords
preparation
product
ethyl
therapeutically active
indolokinolizindins
Prior art date
Application number
NO783958A
Other languages
Norwegian (no)
Other versions
NO151288C (en
NO783958L (en
Inventor
Andre Buzas
Original Assignee
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras filed Critical Scras
Publication of NO783958L publication Critical patent/NO783958L/en
Publication of NO151288B publication Critical patent/NO151288B/en
Publication of NO151288C publication Critical patent/NO151288C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Description

Denne oppfinnelse angår fremstilling av nye indolo-(2,3-a)kinolizidiner. This invention relates to the preparation of new indolo-(2,3-a)quinolizidines.

De nye indolo(2,3-a)kinolizidiner som fremstilles i henhold til oppfinnelsen, har de generelle formler (I) og (II) The new indolo(2,3-a)quinolizidines produced according to the invention have the general formulas (I) and (II)

hvor R betyr where R means

hvor R' er where R' is

- et til C,. alkoksyradikal; eller - one to C,. alkoxy radical; or

- et trimetoksy-substituert fenylradikal; - a trimethoxy-substituted phenyl radical;

Ifølge oppfinnelsen fremstilles også syreaddisjonssaltene av de ovenstående forbindelser. According to the invention, the acid addition salts of the above compounds are also produced.

Forbindelsene som fremstilles i henhold til oppfinnelsen er særlig av interesse på grunn av sin virkning på blodsirkulasjonen i hjernen. En eller flere av forbindelsene fremstilt i henhold til oppfinnelsen kan innarbeides i terapeutiske preparater sammen med et terapeutisk godtagbart fortynningsmiddel eller bæremiddel. The compounds produced according to the invention are of particular interest because of their effect on blood circulation in the brain. One or more of the compounds produced according to the invention can be incorporated into therapeutic preparations together with a therapeutically acceptable diluent or carrier.

De ovenstående forbindelser fremstilles i henhold til oppfinnelsen ved at en tilsvarende forbindelse hvor R betyr -CI^-NI^» kondenseres med en forbindelse med formelen R'COHal, hvor R' er som innledningsvis angitt, og Hal er halogen. Utgangsmaterialet kan fremstilles ved at 2-aminoetyl-3-indol kondenseres med l-klor-4-cyano-4-klorkarbonyl-heksan, for å danne det tilsvarende amid; amidet underkastes sterkt basiske betingelser for å eliminere HC1 og frembringe ringdannelse ved nitrogenatomet på 3-indol-substituenten; kinolizidin-ringdannelse av produktet frem-bringes ved å behandle det med et dehydratiseringsmiddel fulgt av et perkloratsalt; det resulterende kinolizidiniumperklorat hydro-generes for å frembringe den tilsvarende 1-etyl-l-cyano-indolo-(2,3-a)-kinolizidin-isomerblanding, og isomerene separeres. Aminometyl-utgangsmaterialet oppnås derefter. The above compounds are prepared in accordance with the invention by condensing a corresponding compound where R means -CI^-NI^» with a compound of the formula R'COHal, where R' is as stated at the outset, and Hal is halogen. The starting material can be prepared by condensing 2-aminoethyl-3-indole with 1-chloro-4-cyano-4-chlorocarbonyl-hexane to form the corresponding amide; the amide is subjected to strongly basic conditions to eliminate HCl and produce ring formation at the nitrogen atom of the 3-indole substituent; quinolizidine cyclization of the product is produced by treating it with a dehydrating agent followed by a perchlorate salt; the resulting quinolizidinium perchlorate is hydrogenated to produce the corresponding 1-ethyl-1-cyano-indolo-(2,3-a)-quinolizidine isomeric mixture, and the isomers are separated. The aminomethyl starting material is then obtained.

I de følgende skjemaer betegner: In the following forms denotes:

Typiske reaksjonsbetingelser for hvert reaksjonstrinn er som illustrert i de følgende eksempler. Andre betingelser for ut-førelse av de samme omdannelser vil være åpenbare for fagfolk. Typical reaction conditions for each reaction step are as illustrated in the following examples. Other conditions for carrying out the same conversions will be obvious to those skilled in the art.

De følgende eksempler skal tjene til å illustrere oppfinnelsen Eksempel 1 The following examples shall serve to illustrate the invention Example 1

(a) Fremstilling av 3-[ 2'-(2"-cyano-2"-etyl-5"-kl or-valeroylamino)- etyl]- indol (a) Preparation of 3-[2'-(2"-cyano-2"-ethyl-5"-chloro-valeroylamino)-ethyl]-indole

I en 1 liters kolbe ble anbragt 31 g (0,19 4 mol) tryptamin, 500 ml diklormetan og 20 g (0,198 mol) trietylamin. Blandingen ble avkjølt til 0°C over is, og det ble tilsatt 31 g (0.19 4 mol) of tryptamine, 500 ml of dichloromethane and 20 g (0.198 mol) of triethylamine were placed in a 1 liter flask. The mixture was cooled to 0°C over ice and it was added

40 g (0,192 mol) 2-cyano-2-ety1-5-klor-valeroylklorid oppløst i 150 ml metyldiklorid. Efter 2 timer ved romtemperatur ble blandingen vasket med vann, derefter med 10%ig saltsyre og derefter med 10%ig natriumhydroksyd. Den ble tørret, og oppløsningsmidlet ble fjernet ved avdampning. Produktet, omkrystallisert fra isopropyleter/petroleter, smeltet ved 120°C (utbytte 40 g). Analyseresultatene er som følger: 40 g (0.192 mol) of 2-cyano-2-ethyl-5-chloro-valeroyl chloride dissolved in 150 ml of methyl dichloride. After 2 hours at room temperature, the mixture was washed with water, then with 10% hydrochloric acid and then with 10% sodium hydroxide. It was dried and the solvent was removed by evaporation. The product, recrystallized from isopropyl ether/petroleum ether, melted at 120°C (yield 40 g). The analysis results are as follows:

Beregnet for C^H^t^ClO: C 65,0, H 6,64, N 12,65% Calculated for C^H^t^ClO: C 65.0, H 6.64, N 12.65%

Funnet: C 64,03, H.6,78, N 12,60%. Found: C 64.03, H.6.78, N 12.60%.

(b) Fremstilling av 1-[ ( 2'- indol- 3"- yl- etyl)- 3- etyl- 3- cyano]-2- piperidon (b) Preparation of 1-[(2'-indol-3"-yl-ethyl)-3-ethyl-3-cyano]-2- piperidone

I en 1 liter rundbunnet kolbe ble anbragt 22 g 22 g were placed in a 1 liter round-bottomed flask

(0,0665 mol) av produktet fra trinn (a) ovenfor, 200 ml tetrahydrofuran og 300 ml t-butanol. Blandingen ble avkjølt til 0°C over is, og det ble tilsatt, i små mengder, 8,5 g (0,076 mol) kalium-tert.butoksyd. Efter 2 timer ved romtemperatur ble blandingen redusert i volum og hydrolysert. Den organiske fase ble ekstrahert med metylendiklorid, vasket med vann, tørret og oppløsningsmidlet ble fjernet ved inndampning. Det ønskede produkt, omkrystallisert fra etanol/eter 50/50 smeltet ved 180°C (utbytte 15 g, 80%). Analyseresultatene er som følger: (0.0665 mol) of the product from step (a) above, 200 ml of tetrahydrofuran and 300 ml of t-butanol. The mixture was cooled to 0°C over ice and 8.5 g (0.076 mol) potassium tert-butoxide was added in small amounts. After 2 hours at room temperature, the mixture was reduced in volume and hydrolysed. The organic phase was extracted with methylene dichloride, washed with water, dried and the solvent was removed by evaporation. The desired product, recrystallized from ethanol/ether 50/50 melted at 180°C (yield 15 g, 80%). The analysis results are as follows:

Beregnet for ClgH23N30: C 73,2, H 7,1 N 14,2% Calculated for ClgH23N30: C 73.2, H 7.1 N 14.2%

Funnet: C 72,46 H 7,15, N 14,01% (c) Fremstilling av l- etyl- l- cyano- 5, 12b- didehydro- indolo-( 2, 3- a) kinolizidinium- perklorat Found: C 72.46 H 7.15, N 14.01% (c) Preparation of l-ethyl-l-cyano-5,12b-didehydro-indolo-(2,3-a)quinolizidinium-perchlorate

I en 1 liters kolbe ble anbragt under omrøring 50 g (0,169 mol) av produktet fra trinn (b) ovenfor og 700 ml fosforyl-klorid. Efter oppvarmning under tilbakeløpskjøling i 20 timer 50 g (0.169 mol) of the product from step (b) above and 700 ml of phosphoryl chloride were placed in a 1 liter flask with stirring. After heating under reflux cooling for 20 hours

ble rekasjonsblandingen konsentrert og ekstrahert 2 eller 3 ganger med 500 ml metylendiklorid som derefter ble fjernet ved avdampning. Produktet ble tatt opp i 300 ml metylendiklorid og avkjølt over is, og 300 ml av en oppløsning av litiumperklorat (1 mol) ble tilsatt the reaction mixture was concentrated and extracted 2 or 3 times with 500 ml of methylene dichloride which was then removed by evaporation. The product was taken up in 300 ml of methylene dichloride and cooled over ice, and 300 ml of a solution of lithium perchlorate (1 mol) was added

under kraftig omrøring. Det ble dannet et gult bunnfall som efter oinkrystal lise ring fra metanol smeltet ved 260°C (utbytte 44 g, 70%). Analyseresultatene er som følger: under vigorous stirring. A yellow precipitate was formed which, after recrystallization from methanol, melted at 260°C (yield 44 g, 70%). The analysis results are as follows:

IR 3400 cm<-1> NH indol IR 3400 cm<-1> NH indole

2260 cm"<1> C=N 2260 cm"<1> C=N

1620 cm"<1> C=N<+ >(d) Fremstilling av 1- etyl- 1- cyano- indolo( 2, 3- a) kinolizidin 1620 cm"<1> C=N<+ >(d) Preparation of 1- ethyl- 1- cyano- indolo( 2, 3- a) quinolizidine

( 12b- H, l- C^H^ trans- isomer) (12b- H, l- C^H^ trans isomer)

I en i 1 liters rundbunnet kolbe ble anbragt 200 ml metanol, 100 ml metylendiklorid og 13,5 g (0,036 mol) av perkloratproduktet fra trinn (c) ovenfor. Kolben ble avkjølt til ca. 5°C, og 5 g natriumborhydrat ble tilsatt i små mengder. Oppløsningen ble derefter omrørt i 2 timer ved romtemperatur, konsentrert, vasket med vann og ekstrahert med metylendiklorid. Efter tørring og fjernelse av oppløsningsmidlet fikk man 8 g gule krystaller, 200 ml of methanol, 100 ml of methylene dichloride and 13.5 g (0.036 mol) of the perchlorate product from step (c) above were placed in a 1 liter round bottom flask. The flask was cooled to approx. 5°C, and 5 g of sodium borohydrate were added in small amounts. The solution was then stirred for 2 hours at room temperature, concentrated, washed with water and extracted with methylene dichloride. After drying and removal of the solvent, 8 g of yellow crystals were obtained,

som efter omkrystallisering fra isopropyleter smeltet ved 160°C (utbytte 80%). Analyseresultatene er som følger: IR 3420 cm"1 ) which after recrystallization from isopropyl ether melted at 160°C (yield 80%). The analysis results are as follows: IR 3420 cm"1 )

3440 cm"<1> ) 3440 cm"<1> )

2760 cm"<1>' ) 2760 cm"<1>' )

2 800 cm ) NH- og Bohlmann-bånd 2,800 cm ) NH and Bohlmann bands

2250 cm"<1> CN 2250 cm"<1> CN

NMR (dimetylsulfoksyd, dg, 80 MHz) 6 NMR (dimethyl sulfoxide, dg, 80 MHz) 6

0,86, 3H i(t) (CH ) 0.86, 3H in (t) (CH )

3,77, 1H (s) (H ved Cn ) 3.77, 1H (s) (H at Cn )

— 9a — 9a

9,66, 1H (s) (NH) 9.66, 1H (s) (NH)

Beregnet for c1sH21N3: C 77'7' K 7. 2, N 15,2% Calculated for c1sH21N3: C 77'7' K 7.2, N 15.2%

Funnet: C 77,55, H 7,32, N 15,10%. Found: C 77.55, H 7.32, N 15.10%.

(e) Fremstilling av 1- etyl- l- cyano- indolo( 2, 3- a) kinolizidin (e) Preparation of 1-ethyl-1-cyano-indolo(2,3-a)quinolizidine

( 12b- H, 1- C2H5 cis- isomer) ( 12b- H, 1- C2H5 cis- isomer)

I en 1 liters kolbe ble anbragt 19 g av perkloratproduktet fra trinn (c) ovenfor, 300 ml 95%ig etanol og 40 g sinkpulver. Derefter ble 100 ml konsentrert saltsyre tilsatt. Svakt tilbakeløp kunne iakttas under tilsetning av syren. Blandingen fikk stå 19 g of the perchlorate product from step (c) above, 300 ml of 95% ethanol and 40 g of zinc powder were placed in a 1 liter flask. Then 100 ml of concentrated hydrochloric acid was added. Weak reflux could be observed during addition of the acid. The mixture was allowed to stand

ved romtemperatur i 10 timer. Den ble derefter konsentrert, vasket med vann og ekstrahert med metylendiklorid. Den ble gjort alkalisk med natriumhydroksyd og filtrert gjennom "Celite". at room temperature for 10 hours. It was then concentrated, washed with water and extracted with methylene dichloride. It was made alkaline with sodium hydroxide and filtered through Celite.

Efter dekantering, tørring og avdampning av oppløsningsmidlene fikk man 6 g av et produkt, uoppløselig i eter, med smeltepunkt 250°C. Analyseresultatene er som følger: After decantation, drying and evaporation of the solvents, 6 g of a product, insoluble in ether, with a melting point of 250°C were obtained. The analysis results are as follows:

IR 3410 cm"<1> (NH) IR 3410 cm"<1> (NH)

2260 cm"<1> (CN) 2260 cm"<1> (CN)

Beregnet for <C>18H21<N>3<*1/>4H20: C 76'5' H 7'60' N 14,85% Calculated for <C>18H21<N>3<*1/>4H20: C 76'5' H 7'60' N 14.85%

Funnet: C 76,59, H 7,80, N 14,55%. Found: C 76.59, H 7.80, N 14.55%.

Eterekstraktene ble konsentrert for å gi 4 g (totalt utbytte 71,5%) av cis-isomeren av det samme produkt som trinn (d) ovenfor. The ether extracts were concentrated to give 4 g (total yield 71.5%) of the cis isomer of the same product as step (d) above.

NMR (dimetylsulfoksyd d,, 80 MH_) 6: NMR (dimethylsulfoxide d,, 80 MH_) 6:

o Land L

1,05, 3H (t) (CH3) 1.05, 3H (t) (CH3)

3,45, 1H (s) (H ved CQ ) 3.45, 1H (s) (H at CQ )

10,32, 1H (s) (NH) 10.32, 1H (s) (NH)

(f) Fremstilling av 1- etyl- l- aminometyl- indolo( 2, 3- a)-kinolizidin ( 12b- H, 1- C,,H5 trans- isomer II) (f) Preparation of 1-ethyl-1-aminomethyl-indolo(2,3-a)-quinolizidine (12b-H,1-C,,H5 trans-isomer II)

I en 1 liters kolbe ble anbragt 4 g litiumaluminium-hydrid og 400 ml tørr eter. Kolben ble avkjølt til en temperatur mellom 0 og 5°C, og det ble tilsatt, i små mengder, 8,9 g av produktet fra trinn (d) ovenfor. Efter at kolben hadde fått stå 4 g of lithium aluminum hydride and 400 ml of dry ether were placed in a 1 liter flask. The flask was cooled to a temperature between 0 and 5°C and 8.9 g of the product from step (d) above was added, in small portions. After the flask had been allowed to stand

i 1 time ved romtemperatur, ble 60 ml tørr tetrahydrofuran tilsatt. Blandingen ble oppvarmet i 2 timer under tilbakeløpskjøling. Efter avkjølingen ble det tilsatt dråpevis 40 ml vann fulgt av 200 ml metylendiklorid. Blandingen ble omrørt i 15 minutter. Efter filtrering over "Celite", tørring og konsentrering av filtratet fikk man 7,2 g hvite krystaller som efter omkrystallisering fra eter smeltet ved 175°C (80% utbytte). for 1 hour at room temperature, 60 ml of dry tetrahydrofuran was added. The mixture was heated for 2 hours under reflux. After cooling, 40 ml of water was added dropwise, followed by 200 ml of methylene dichloride. The mixture was stirred for 15 minutes. After filtration over "Celite", drying and concentration of the filtrate, 7.2 g of white crystals were obtained which after recrystallization from ether melted at 175°C (80% yield).

Analyseresultatene er som følger: The analysis results are as follows:

IR 3280, 3190 cm"<1> NH--1 IR 3280, 3190 cm"<1> NH--1

3350 cm NH indol 3350 cm NH indole

CN-toppen ved ca. 2250 cm 1 var fraværende. The CN peak at approx. 2250 cm 1 was absent.

Beregnet for C^H^: C 76,4, H 8,85, N 14,8% Calculated for C^H^: C 76.4, H 8.85, N 14.8%

Funnet: C 75,85, H 8,90, N 15,52%. Found: C 75.85, H 8.90, N 15.52%.

g) 1- etoksykarbonylaminometyl- l- etyl- indolo( 2, 3- a) kinolizidin-hydroklorid ( 12b- H, 1- C^H^ trans- isomer II) g) 1- ethoxycarbonylaminomethyl- 1- ethyl- indolo( 2, 3- a) quinolizidine hydrochloride ( 12b- H, 1- C^H^ trans-isomer II)

Til' en oppløsning av 2 g (0,00705 mol) av trans-produktet II fra (f) i 20 ml dimetoksyetan, avkjølt til 0°C, ble satt alternerende for å holde pH basisk, porsjoner av: 800 mg etylklorformiat i oppløsning i 5 ml dimetoksyetan, og 750 mg natriumkarbonat i oppløsning i 5 ml vann. To a solution of 2 g (0.00705 mol) of the trans-product II from (f) in 20 ml of dimethoxyethane, cooled to 0°C, were added alternately to keep the pH basic, portions of: 800 mg of ethyl chloroformate in solution in 5 ml of dimethoxyethane, and 750 mg of sodium carbonate in solution in 5 ml of water.

Efter at reaksjonsblandingen hadde fått stå i 3 timer ved omgivelsestemperatur ble produktet ekstrahert med diklormetan, diklormetanekstrakten ble vasket med vann, tørret og inndampet til tørrhet. Produktet ble omkrystallisert fra etanol. After the reaction mixture had been allowed to stand for 3 hours at ambient temperature, the product was extracted with dichloromethane, the dichloromethane extract was washed with water, dried and evaporated to dryness. The product was recrystallized from ethanol.

Vekt: 2 g, utbytte: 80%, Sm.p.: 140°C. Weight: 2 g, yield: 80%, Melting point: 140°C.

Resultatene av mikroanalyse er som følger: Beregnet for c2iH29<N>3°2<:> C 71'0' H 8'17' N H/8% Funnet: C 70,94, H 8,16, N 11,54%. The results of microanalysis are as follows: Calculated for c2iH29<N>3°2<:> C 71'0' H 8'17' N H/8% Found: C 70.94, H 8.16, N 11.54% .

Hydrokloridsaltet ble dannet av de ovenstående 2 g produkt ved tilsetning av 4N HC1 i 20 ml etanol. The hydrochloride salt was formed from the above 2 g of product by the addition of 4N HCl in 20 ml of ethanol.

Vekt: 2 g, utbytte: 90%, sm.p.: 260°C. Weight: 2 g, yield: 90%, m.p.: 260°C.

Eksempel 2 Example 2

1-( 3', 4', 5'- trimetoksybenzoylaminometyl)- 1- etyl- indolo-( 2 , 3- a) - kinolizidin- hydroklorid ( 12b- H, l- C^H^ trans- isomer II) 1-(3',4',5'-trimethoxybenzoylaminomethyl)-1-ethyl-indolo-(2,3-a)-quinolizidine hydrochloride (12b-H,l-C^H^ trans-isomer II)

Inn i en trehalset kolbe med volum på 250 ml utstyrt Into a three-necked flask with a volume of 250 ml equipped

med en rører, en CaC^-felle, et termometer og en dryppetrakt ble innført 2,85 g av transproduktet II fra eksempel 2(f), 1,1 g trietylamin og 50 ml diklormetan. with a stirrer, a CaC₂ trap, a thermometer and a dropping funnel, 2.85 g of the transproduct II from example 2(f), 1.1 g of triethylamine and 50 ml of dichloromethane were introduced.

Blandingen ble omrørt og avkjølt til 0,2°C. Ved denne temperatur ble det langsomt tilsatt 2,31 g 3,4,5-trimetoksybenzoyl-klorid i 15 ml diklormetan. Tilsetningen fant sted over en periode på 15 til 20 minutter, hvorefter reaksjonsblandingen ble omrørt i 1 time ved 0°C og derefter i 15 timer ved romtemperatur. The mixture was stirred and cooled to 0.2°C. At this temperature, 2.31 g of 3,4,5-trimethoxybenzoyl chloride in 15 ml of dichloromethane were added slowly. The addition took place over a period of 15 to 20 minutes, after which the reaction mixture was stirred for 1 hour at 0°C and then for 15 hours at room temperature.

Reaksjonsblandingen ble derefter vasket flere ganger med vann, derefter med 10%ig vandig natriumhydroksyd og derefter igjen med vann. Den ble tørret over natriumsulfat og konsentrert for å danne en ikke-krystallinsk masse med tekstur som marengs og med smeltepunkt nær 100°C. The reaction mixture was then washed several times with water, then with 10% aqueous sodium hydroxide and then again with water. It was dried over sodium sulfate and concentrated to form a non-crystalline mass with a meringue texture and melting point near 100°C.

TLC: metylenklorid/metanol: 90/10, Rf = 8/10 TLC: methylene chloride/methanol: 90/10, Rf = 8/10

IR 3230 cm"1 NH IR 3230 cm"1 NH

3190 cm"<1> NH 3190 cm"<1> NH

2 750 og 2800 cm"<1>Bohlmann bånd 2,750 and 2,800 cm"<1>Bohlmann band

1640 cm <1> C=0 amid 1640 cm <1> C=0 amide

Mengde base med HC104: 97% Amount of base with HC104: 97%

Mengden av base bestemt ved en anhydro-titrimetrisk metode under anvendelse av perklorsyre i iseddik. The amount of base determined by an anhydro-titrimetric method using perchloric acid in glacial acetic acid.

For å fremstille hydrokloridsaltet ble det ovenstående produkt oppløst i en 1:1 blanding av diisopropyleter og isopropanol, og 4N saltsyre ble tilsatt. Hydrokloridsaltet krystalliserte i varm tilstand og ble filtrert varmt og vasket med etanol for å gi 4,5 g (88% utbytte) av produktet. To prepare the hydrochloride salt, the above product was dissolved in a 1:1 mixture of diisopropyl ether and isopropanol, and 4N hydrochloric acid was added. The hydrochloride salt crystallized while hot and was filtered hot and washed with ethanol to give 4.5 g (88% yield) of the product.

TLC: metylenklorid/metanol: 90/10, Rf = 8/10 TLC: methylene chloride/methanol: 90/10, Rf = 8/10

Sm.p. : 210°C, Koffler) Sm.p. : 210°C, Koffler)

Mengde av hydroklorid: 100% (1 funksjon). Amount of hydrochloride: 100% (1 function).

Mikroanalyse ga de følgende resultater: Microanalysis gave the following results:

Beregnet for C28<H>35N3°4'HC1: C 65'45' H 7'00' N 8,18% Calculated for C28<H>35N3°4'HC1: C 65'45' H 7'00' N 8.18%

Funnet: C 64,34, H 7,17, N 8,11% Found: C 64.34, H 7.17, N 8.11%

C 64,15, H 7,16, N 7,96%. C 64.15, H 7.16, N 7.96%.

Claims (1)

Analogifremgangsmåte for fremstilling av terapeutisk aktiveAnalogy method for the production of therapeutically active indolo(2,3-a)kinolizidiner med de generelle formler (I) og (II)indolo(2,3-a)quinolizidines of the general formulas (I) and (II) hvor R' er - et til Cj- alkoksyradikal; eller - et trimetoksy-substituert fenylradikal;where R' is - a to C 1 - alkoxy radical; or - a trimethoxy-substituted phenyl radical; karakterisert ved at en tilsvarende forbindelse hvor R betyr -CI^-NH^/ kondenseres med en forbindelse med formelen R'COHal, hvor R' er som innledningsvis angitt, og Hal er halogen.characterized in that a corresponding compound where R means -CI^-NH^/ is condensed with a compound of the formula R'COHal, where R' is as indicated at the outset, and Hal is halogen.
NO783958A 1977-11-25 1978-11-23 ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS NO151288C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4920177 1977-11-25

Publications (3)

Publication Number Publication Date
NO783958L NO783958L (en) 1979-05-28
NO151288B true NO151288B (en) 1984-12-03
NO151288C NO151288C (en) 1985-03-13

Family

ID=10451538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO783958A NO151288C (en) 1977-11-25 1978-11-23 ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS

Country Status (28)

Country Link
JP (1) JPS6147838B2 (en)
AR (1) AR218514A1 (en)
AT (1) AT372384B (en)
AU (1) AU529108B2 (en)
BE (1) BE872134A (en)
CA (1) CA1100959A (en)
CH (1) CH641181A5 (en)
DE (1) DE2851028A1 (en)
DK (1) DK154430C (en)
EG (1) EG13683A (en)
ES (1) ES475328A1 (en)
FI (1) FI64372C (en)
FR (2) FR2423492A1 (en)
HK (1) HK60884A (en)
IE (1) IE47518B1 (en)
IN (1) IN151146B (en)
IT (1) IT1160263B (en)
LU (1) LU80576A1 (en)
MX (1) MX5529E (en)
MY (1) MY8500029A (en)
NL (1) NL7811562A (en)
NO (1) NO151288C (en)
NZ (1) NZ188974A (en)
PT (1) PT68825A (en)
SE (2) SE431650B (en)
SG (1) SG61182G (en)
WO (1) WO1979000319A1 (en)
ZA (1) ZA786426B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175900D1 (en) * 1981-11-18 1987-03-12 Thal Claude Indoloquinolizine derivatives, process for their preparation and their therapeutic use
FR2529552B1 (en) * 1982-07-05 1985-09-27 Centre Nat Rech Scient NOVEL PROCESS FOR THE PREPARATION OF VINDOLINE SYNTHESIS INTERMEDIATES AND SYNTHESIS INTERMEDIATES
HU191454B (en) * 1984-10-05 1987-02-27 Richter Gedeon Vegyeszeti Gyar Rt.,Hu Process for producing amides of oktahydro-indolo/2,3-a/quinolyzin-1-yl-alkanecarboxylic acids and pharmaceutically acceptable acid additional salts thereof
HU194220B (en) * 1985-04-19 1988-01-28 Richter Gedeon Vegyeszet Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof
HU195214B (en) * 1985-04-19 1988-04-28 Richter Gedeon Vegyeszet Process for producing 12b-substituted-1-(hydroxymethyl)-octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
WO1995000502A1 (en) * 1993-06-18 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Novel intermediate for synthetic use and process for producing aminopiperazine derivative
FR2713643B1 (en) * 1993-12-14 1996-06-07 Adir New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them.
FR2713644B1 (en) * 1993-12-14 1996-02-09 Adir New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them.
RU2305815C2 (en) 2002-06-24 2007-09-10 Сэн-Гобэн Изовер Insulating panel for distributing passage
FR2911142A1 (en) * 2007-01-05 2008-07-11 Servier Lab New amino-pyrroloindole and amino-pyridazinoindole derivatives, are tyrosine hydroxylase inducers, useful e.g. for treating anxiety, depression or memory loss
FR2911141B1 (en) * 2007-01-05 2009-02-20 Servier Lab NOVEL TRIAZABENZO [A] NAPHTHO [2,1,8-CDE] AZULENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2911143A1 (en) * 2007-01-05 2008-07-11 Servier Lab Use of neuroprotective compounds to prepare medicaments for treating neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167366B (en) * 1972-09-06 1975-09-27
BE802387A (en) * 1973-07-16 1973-11-16 Omnium Chimique Sa PROCESS FOR PREPARING VINCAMONE AND EPI-21 VINCAMONE FROM TABERSONIN AND NEW INDOLIC DERIVATIVES.
HU169916B (en) * 1974-09-27 1977-02-28
HU171165B (en) * 1974-11-26 1977-11-28 Richter Gedeon Vegyeszet Process for producing oktahydro-indolo-bracket-2,3-a-bracket closed-quinolizine derivatives
FR2315277A1 (en) * 1975-06-25 1977-01-21 Anvar NEW PENTACYCLIC DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
FR2409755A1 (en) 1979-06-22
NO151288C (en) 1985-03-13
DK524978A (en) 1979-05-26
IE782328L (en) 1979-05-25
EG13683A (en) 1982-09-30
PT68825A (en) 1978-12-01
IN151146B (en) 1983-02-26
WO1979000319A1 (en) 1979-06-14
FR2423492B1 (en) 1980-12-05
NZ188974A (en) 1989-10-27
SE431650B (en) 1984-02-20
DK154430B (en) 1988-11-14
ZA786426B (en) 1979-10-31
FR2409755B1 (en) 1980-08-01
LU80576A1 (en) 1979-03-22
BE872134A (en) 1979-03-16
AU4187478A (en) 1979-05-31
HK60884A (en) 1984-08-10
SG61182G (en) 1985-02-15
MX5529E (en) 1983-09-23
ES475328A1 (en) 1979-04-01
IT7830171A0 (en) 1978-11-24
JPS6147838B2 (en) 1986-10-21
SE7906287L (en) 1979-07-23
FI64372B (en) 1983-07-29
FI783581A (en) 1979-05-26
IT1160263B (en) 1987-03-11
FR2423492A1 (en) 1979-11-16
CH641181A5 (en) 1984-02-15
AR218514A1 (en) 1980-06-13
IE47518B1 (en) 1984-04-04
JPS54500053A (en) 1979-11-08
NO783958L (en) 1979-05-28
NL7811562A (en) 1979-05-29
CA1100959A (en) 1981-05-12
SE435622B (en) 1984-10-08
DE2851028A1 (en) 1979-05-31
FI64372C (en) 1983-11-10
DK154430C (en) 1989-04-17
AU529108B2 (en) 1983-05-26
AT372384B (en) 1983-09-26
MY8500029A (en) 1985-12-31
ATA837478A (en) 1983-02-15
SE8007845L (en) 1980-11-07
DE2851028C2 (en) 1990-05-03

Similar Documents

Publication Publication Date Title
NO151288B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INDOLOKINOLIZINDINS
JPH01238571A (en) Pyrrolopyridine-acetonitriles and acetamides, and use thereof as herbicide
SE452459B (en) INDOL-5-METANESULPHONAMIDE, A PHARMACEUTICAL COMPOSITION AND A PROCEDURE FOR PREPARING THE SUBSTANCE
NO312669B1 (en) Non-peptide bombesin receptor antagonists, their use and pharmaceutical preparations containing such
NO165343B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTIC ACTIVE 3- (2-AMINOETHYL) INDOLES.
DK157995B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF INCIDENTAL DERIVATIVES
NO161562B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ERGOLIN DERIVATIVES.
Hermkens et al. Syntheses of 1, 3-disubstituted N-oxy-β-carbolines by the Pictet-Spengler reactions of N-oxy-tryptophan and-tryptamine derivatives
NO174773B (en) Process for Preparation of Quinolone Carboxylic Acids
DK170044B1 (en) Process for Preparation of N-Substituted Dihydrolyseric Acid Derivatives
SU683623A3 (en) Method of the preparation of purine derivatives or their salts
US4614806A (en) Process for the asymmetric synthesis of chiral indoline-2-carboxylic acids
US4353911A (en) Indolo(2,3-a)quinolizidines, useful in increasing femoral and vertebral blood flow
Kim Synthesis of 1, 2, 3, 4, 8, 9, 10, 11‐octahydro‐[1, 4] diazepino [6, 5, 4‐jk] earbazole and related compounds
NO178373B (en) Process for the preparation of therapeutically active ergoline derivatives
KR900004002B1 (en) 5-thioxo-2-imidazolinyl benzoic acids
US4584385A (en) Antibacterial 2-amino-oxazolinones and process therefor
JPS6148839B2 (en)
DK169970B1 (en) Intermediates for use in the preparation of pyrimido [4,5-g] quinoline derivatives or salts thereof
US4550165A (en) Process for producing 1,2,5,6-tetrahydro-4H-pyrrolo-[3,2,1-ij]-quinolin-4-one
HU194164B (en) Process for production of 1,2-dihydroxi-3-//2-indolil-1,1-dialkyl-ethil/-amin/-prophanes
Brandao et al. A novel way of synthesis of l, 3, 5-trisubstituted-2-thioxoimidazolidinones
US4595755A (en) 5-halo-1,2,3-(1,2-dihydropyrrolo)-4-quinolones
US4062891A (en) N-formyl-2,3,5,6-dibenzobicyclo[5.1.0]octan-4-methylamine
CA2028953A1 (en) Process for the preparation of quinazoline derivatives